ZAI LAB LIMITED - AMERICAN DEPOSITARY SHARES

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

07 Nov 2023 16:05:01 By Nasdaq GlobeNewswire

Zai Lab Announces Participation in November Investor Conferences

26 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023

18 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China

18 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with NTRK-positive TKI-pretreated advanced solid tumors in China

30 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Participation in September Investor Conferences

29 Aug 2023 07:38:50 By Nasdaq GlobeNewswire

Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates

07 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Zai Lab to Announce Second Quarter 2023 Financial Results and Corporate Updates on August 7, 2023

20 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

JAMA Oncology Publishes Data from Zai Lab Study Demonstrating Significant Reduction in Disease Progression or Death with ZEJULA (Niraparib) Maintenance Therapy in Broad Population of Advanced Ovarian Cancer Patients

19 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

17 Jul 2023 01:03:39 By Nasdaq GlobeNewswire

Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer

14 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

10 Jul 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer

06 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

30 Jun 2023 09:22:47 By Nasdaq GlobeNewswire

Zai Lab Announces NDA Acceptance of Repotrectinib for Patients with ROS1-positive NSCLC by China’s NMPA

28 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

06 Jun 2023 08:05:52 By Nasdaq GlobeNewswire

Zai Lab to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting

01 Jun 2023 16:03:00 By Nasdaq GlobeNewswire

Zai Lab Announces Participation in June Investor Conferences

25 May 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces That Repotrectinib Granted Priority Review by China’s NMPA

18 May 2023 07:30:00 By Nasdaq GlobeNewswire

Zai Lab Announces First Quarter 2023 Financial Results and Corporate Updates

09 May 2023 16:01:00 By Nasdaq GlobeNewswire